HC Wainwright Has Optimistic Outlook of ACRV Q1 Earnings

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Research analysts at HC Wainwright upped their Q1 2026 earnings per share (EPS) estimates for Acrivon Therapeutics in a report issued on Thursday, March 19th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.53) per share for the quarter, up from their prior forecast of ($0.54). HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.61) EPS, Q4 2026 earnings at ($0.66) EPS, FY2026 earnings at ($2.38) EPS, FY2027 earnings at ($1.67) EPS, FY2028 earnings at ($1.11) EPS, FY2029 earnings at ($0.84) EPS and FY2030 earnings at $0.04 EPS.

Several other equities analysts have also weighed in on ACRV. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Acrivon Therapeutics in a research report on Monday, December 29th. Wall Street Zen downgraded shares of Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, March 1st. Piper Sandler raised their price target on shares of Acrivon Therapeutics from $6.00 to $8.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Acrivon Therapeutics in a research note on Monday, March 2nd. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Acrivon Therapeutics has an average rating of “Moderate Buy” and an average price target of $11.67.

Acrivon Therapeutics Stock Performance

Shares of NASDAQ ACRV opened at $1.66 on Monday. The business has a 50 day simple moving average of $1.71 and a 200 day simple moving average of $1.95. Acrivon Therapeutics has a 52 week low of $1.05 and a 52 week high of $5.65. The stock has a market cap of $64.31 million, a price-to-earnings ratio of -0.82 and a beta of 1.79.

Acrivon Therapeutics (NASDAQ:ACRV) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.49) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.49).

Hedge Funds Weigh In On Acrivon Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS Group AG raised its position in shares of Acrivon Therapeutics by 150,057.8% in the third quarter. UBS Group AG now owns 683,218 shares of the company’s stock valued at $1,237,000 after purchasing an additional 682,763 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Acrivon Therapeutics by 1.7% during the 4th quarter. Renaissance Technologies LLC now owns 634,169 shares of the company’s stock worth $1,528,000 after buying an additional 10,769 shares during the period. Marshall Wace LLP boosted its holdings in shares of Acrivon Therapeutics by 231.4% during the 4th quarter. Marshall Wace LLP now owns 496,081 shares of the company’s stock worth $1,196,000 after buying an additional 346,366 shares during the period. Jane Street Group LLC grew its stake in Acrivon Therapeutics by 18.3% in the 4th quarter. Jane Street Group LLC now owns 342,071 shares of the company’s stock valued at $824,000 after buying an additional 52,823 shares during the last quarter. Finally, Two Sigma Investments LP raised its holdings in Acrivon Therapeutics by 76.2% in the 3rd quarter. Two Sigma Investments LP now owns 319,205 shares of the company’s stock worth $578,000 after acquiring an additional 138,033 shares during the period. Institutional investors and hedge funds own 71.62% of the company’s stock.

Insider Buying and Selling at Acrivon Therapeutics

In related news, CEO Peter Blume-Jensen bought 49,000 shares of Acrivon Therapeutics stock in a transaction that occurred on Wednesday, January 14th. The stock was purchased at an average cost of $1.68 per share, for a total transaction of $82,320.00. Following the acquisition, the chief executive officer owned 2,095,771 shares in the company, valued at $3,520,895.28. This trade represents a 2.39% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last quarter, insiders purchased 67,832 shares of company stock valued at $114,534. 8.50% of the stock is currently owned by company insiders.

Key Stories Impacting Acrivon Therapeutics

Here are the key news stories impacting Acrivon Therapeutics this week:

• Positive Sentiment: HC Wainwright raised multiple quarterly and annual EPS estimates (Q1–Q4 2026, FY2026–FY2030), narrowing projected losses and moving FY2030 to a small positive EPS; the firm reiterated a “Buy” rating and a $19 price target. HC Wainwright note
• Neutral Sentiment: The EPS upgrades are incremental (small changes in cents per quarter/year) — they improve the trajectory but do not materially change near-term cash-burn or clinical-development risk; consensus for FY2026 remains a sizeable loss.
• Negative Sentiment: Shares are trading down today amid low liquidity (volume below the three‑month average), below both the 50‑day and 200‑day moving averages, and following recent quarterly results that showed continued losses — all factors that can trigger short‑term selling/pressure in a small‑cap biotech with a high beta.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.